- Home
- ULH vs CAPR Comparison
ULH vs CAPR Comparison
Compare ULH & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ULH
- CAPR
- Stock Information
- Founded
- ULH 1932
- CAPR 2005
- Country
- ULH United States
- CAPR United States
- Employees
- ULH N/A
- CAPR N/A
- Industry
- ULH Trucking Freight/Courier Services
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ULH Industrials
- CAPR Health Care
- Exchange
- ULH Nasdaq
- CAPR Nasdaq
- Market Cap
- ULH 591.6M
- CAPR 600.7M
- IPO Year
- ULH 2005
- CAPR N/A
- Fundamental
- Price
- ULH $23.74
- CAPR $9.97
- Analyst Decision
- ULH Hold
- CAPR Strong Buy
- Analyst Count
- ULH 1
- CAPR 6
- Target Price
- ULH $29.00
- CAPR $41.67
- AVG Volume (30 Days)
- ULH 39.1K
- CAPR 3.3M
- Earning Date
- ULH 07-24-2025
- CAPR 05-13-2025
- Dividend Yield
- ULH 1.74%
- CAPR N/A
- EPS Growth
- ULH N/A
- CAPR N/A
- EPS
- ULH 3.17
- CAPR N/A
- Revenue
- ULH $1,736,518,000.00
- CAPR $17,363,588.00
- Revenue This Year
- ULH N/A
- CAPR $78.79
- Revenue Next Year
- ULH $7.88
- CAPR $158.07
- P/E Ratio
- ULH $7.59
- CAPR N/A
- Revenue Growth
- ULH 1.16
- CAPR N/A
- 52 Week Low
- ULH $20.60
- CAPR $3.52
- 52 Week High
- ULH $53.29
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- ULH 44.56
- CAPR 47.80
- Support Level
- ULH $22.40
- CAPR $9.58
- Resistance Level
- ULH $24.72
- CAPR $10.80
- Average True Range (ATR)
- ULH 0.84
- CAPR 0.96
- MACD
- ULH -0.01
- CAPR 0.13
- Stochastic Oscillator
- ULH 31.76
- CAPR 58.82
About ULH Universal Logistics Holdings Inc.
Universal Logistics Holdings Inc is an asset-light provider of customized transportation and logistics solutions throughout the United States, and in Mexico, Canada and Colombia. It offers services such as truckload, brokerage, intermodal, dedicated, and value-added services. The company reports into four segments namely trucking, intermodal, company-managed brokerage, and contract logistics. The majority of the revenue is earned from the contract logistics segment.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.